Allspring Global Investments Holdings LLC Buys 21,253 Shares of Perrigo Company plc (NYSE:PRGO)

Allspring Global Investments Holdings LLC raised its stake in Perrigo Company plc (NYSE:PRGO) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 715,489 shares of the company’s stock after acquiring an additional 21,253 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.53% of Perrigo worth $23,024,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Dark Forest Capital Management LP bought a new position in shares of Perrigo during the first quarter worth approximately $31,000. Ronald Blue Trust Inc. increased its holdings in shares of Perrigo by 132.3% during the third quarter. Ronald Blue Trust Inc. now owns 1,157 shares of the company’s stock worth $39,000 after purchasing an additional 659 shares during the period. Blue Trust Inc. increased its holdings in shares of Perrigo by 34.5% during the fourth quarter. Blue Trust Inc. now owns 1,556 shares of the company’s stock worth $50,000 after purchasing an additional 399 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Perrigo by 345.5% during the first quarter. NewEdge Advisors LLC now owns 1,430 shares of the company’s stock worth $51,000 after purchasing an additional 1,109 shares during the period. Finally, Fifth Third Bancorp increased its holdings in shares of Perrigo by 39.5% during the third quarter. Fifth Third Bancorp now owns 1,714 shares of the company’s stock worth $55,000 after purchasing an additional 485 shares during the period. 95.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Perrigo

In other Perrigo news, CEO Patrick Lockwood-Taylor purchased 9,500 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was purchased at an average price of $26.54 per share, with a total value of $252,130.00. Following the completion of the purchase, the chief executive officer now owns 20,500 shares of the company’s stock, valued at $544,070. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Perrigo news, EVP Alison Ives purchased 2,490 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was purchased at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the purchase, the executive vice president now owns 16,122 shares of the company’s stock, valued at $439,485.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Patrick Lockwood-Taylor purchased 9,500 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were acquired at an average cost of $26.54 per share, with a total value of $252,130.00. Following the purchase, the chief executive officer now directly owns 20,500 shares of the company’s stock, valued at approximately $544,070. The disclosure for this purchase can be found here. Insiders have purchased 17,990 shares of company stock worth $475,227 over the last quarter. Corporate insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on PRGO shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $42.00 target price on shares of Perrigo in a report on Friday. Piper Sandler increased their price target on shares of Perrigo from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, April 8th. JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th. Finally, StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd.

Perrigo Stock Performance

NYSE PRGO opened at $30.32 on Friday. The company has a current ratio of 1.79, a quick ratio of 1.07 and a debt-to-equity ratio of 0.76. The firm’s 50 day simple moving average is $30.80 and its 200 day simple moving average is $30.82. Perrigo Company plc has a 1 year low of $25.77 and a 1 year high of $40.28.

Perrigo (NYSE:PRGO) last issued its earnings results on Tuesday, February 27th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Perrigo had a negative net margin of 0.27% and a positive return on equity of 7.34%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the business posted $0.75 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. On average, equities analysts expect that Perrigo Company plc will post 2.55 earnings per share for the current fiscal year.

Perrigo Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were given a $0.276 dividend. The ex-dividend date was Thursday, March 7th. This represents a $1.10 dividend on an annualized basis and a yield of 3.64%. This is a positive change from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s dividend payout ratio (DPR) is currently -1,100.00%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.